摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-ethyl-7-ethylsulfonyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate | 79286-90-1

中文名称
——
中文别名
——
英文名称
1-ethyl-7-ethylsulfonyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate
英文别名
ethyl 1-ethyl-7-ethylsulfonyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate;ethyl 1-ethyl-7-ethylsulfonyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylate
1-ethyl-7-ethylsulfonyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylate化学式
CAS
79286-90-1
化学式
C15H17FN2O5S
mdl
——
分子量
356.375
InChiKey
NDESOPVYUOKSCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    24
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    102
  • 氢给体数:
    0
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    通过balz-schiemann反应合成氟化吡啶。新型抗菌性吡啶酮羧酸依诺沙星的替代途径†
    摘要:
    描述了通过Balz-Schiemann反应对2,6-二取代的3-氨基吡啶5和12的氟化。2,6-二氯-3- pyridinediazonium四氟硼酸盐(6)和2-取代的6-乙酰氨基-3- pyridinediazonium四氟硼酸盐13用或不用溶剂加热,得到相应的氟化吡啶7和14分别,以良好产率。通过已知方法将2-取代的6-乙酰氨基-3-氟吡啶(14)转化为一系列的7-取代的1-乙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶- 3-羧酸21包括新的潜在抗菌剂依诺沙星[1-乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-1,8-萘啶-3-羧酸[(2)] 。
    DOI:
    10.1002/jhet.5570210309
  • 作为产物:
    参考文献:
    名称:
    通过balz-schiemann反应合成氟化吡啶。新型抗菌性吡啶酮羧酸依诺沙星的替代途径†
    摘要:
    描述了通过Balz-Schiemann反应对2,6-二取代的3-氨基吡啶5和12的氟化。2,6-二氯-3- pyridinediazonium四氟硼酸盐(6)和2-取代的6-乙酰氨基-3- pyridinediazonium四氟硼酸盐13用或不用溶剂加热,得到相应的氟化吡啶7和14分别,以良好产率。通过已知方法将2-取代的6-乙酰氨基-3-氟吡啶(14)转化为一系列的7-取代的1-乙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶- 3-羧酸21包括新的潜在抗菌剂依诺沙星[1-乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-1,8-萘啶-3-羧酸[(2)] 。
    DOI:
    10.1002/jhet.5570210309
点击查看最新优质反应信息

文献信息

  • An intramolecular cyclization of 7-substituted 6-fluoro- 1,8-naphthyridine and -quinoline derivatives
    作者:Yoshiro Nishimura、Akira Minamida、Jun-Ichi Matsumoto
    DOI:10.1002/jhet.5570250224
    日期:1988.3
    A synthesis of 1,4-oxazine and pyrazine ring systems by an intramolecular cyclization of 7-substituted 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine and -quinoline derivatives having a nitrogen or oxygen nucleophilic site in the C-7 appendage was studied. The in vitro antibacterial activities of compounds prepared by this method were tested.
    通过分子内环合7-取代的1-乙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶和具有氮原子的喹啉衍生物合成1,4-恶嗪和吡嗪环系统研究了C-7附肢中的氧亲核位点。在体外用该方法制备的化合物的抗菌活性进行了测试。
  • Naphthyridine derivatives
    申请人:Dainippon Pharmaceutical Co., Ltd.
    公开号:US04341784A1
    公开(公告)日:1982-07-27
    The present invention provides a 1,8-naphthyridine compound of the formula ##STR1## wherein R is hydrogen, methyl, ethyl or propyl, and a nontoxic pharmaceutically acceptable salt thereof, and a process for preparing a 1,8-naphthyridine compound of the above formula which comprises (A) reacting a compound of the formula ##STR2## wherein Y is halogen, lower alkoxy, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, lower alkylsulfonyloxy or arylsulfonyloxy, and R.sub.1 is hydrogen or lower alkyl, with a compound of the formula ##STR3## wherein R.sub.2 is hydrogen or a protective group for the amino group, and R is as defined above, and when a reaction product in which R.sub.1 is lower alkyl and/or R.sub.2 is the amino protective group is obtained, treating it with an acid or base, and/or reductively cleaving it, (B) decomposing a compound of the formula ##STR4## wherein A .crclbar. is a fluorine-containing anion, and R.sub.1 and R.sub.2 are as defined above, and when a reaction product in which R.sub.1 is lower alkyl and/or R.sub.2 is the amino protective group is obtained, treating it with an acid or base, and/or reductively cleaving it, (C) treating a compound of the formula ##STR5## wherein R'.sub.1 is hydrogen or lower alkyl, R'.sub.2 is hydrogen or a protective group for the amino group, provided that R'.sub.1 and R'.sub.2 are not hydrogen atoms at the same time, and R is as defined above, with an acid or base, and/or reductively cleaving it, and optionally converting the resulting compound to a nontoxic pharmaceutically acceptable salt thereof. The 1,8-naphthyridine compound is useful as an antibacterial agent.
    本发明提供了一种1,8-萘啶化合物,其化学式为##STR1##其中R为氢、甲基、乙基或丙基,以及其非毒性药用可接受的盐,并且提供了一种制备上述化合物的1,8-萘啶化合物的方法,包括(A)将化学式为##STR2##其中Y为卤素、较低烷氧基、较低烷基硫基、较低烷基磺酰基、较低烷基磺酰氧基或芳基磺酰氧基的化合物,R.sub.1为氢或较低烷基,与化学式为##STR3##其中R.sub.2为氢或氨基的保护基,R如上所定义,进行反应,当得到R.sub.1为较低烷基和/或R.sub.2为氨基保护基的反应产物时,用酸或碱处理,和/或还原性裂解它,(B)分解化学式为##STR4##其中A .crclbar.为含氟阴离子,R.sub.1和R.sub.2如上所定义,当得到R.sub.1为较低烷基和/或R.sub.2为氨基保护基的反应产物时,用酸或碱处理,和/或还原性裂解它,(C)用酸或碱处理化学式为##STR5##其中R'.sub.1为氢或较低烷基,R'.sub.2为氢或氨基的保护基,前提是R'.sub.1和R'.sub.2不能同时为氢原子,R如上所定义,并可选择将得到的化合物转化为其非毒性药用可接受的盐。1,8-萘啶化合物可用作抗菌剂。
  • Naphthyridine derivatives, processes for their preparation and pharmaceutical compositions containing them
    申请人:Société anonyme dite: LABORATOIRE ROGER BELLON
    公开号:EP0027752A1
    公开(公告)日:1981-04-29
    The present invention provides a 1,8-naphthyridine compound of the formula wherein R is hydrogen, methyl, ethyl or propyl, and a nontoxic pharmaceutically acceptable salt thereof, -an antibacterial agent comprising said 1,8-naphtyridine compound -and a process for prearing a 1,8-naphtyridine compound of the above formula which comprises (A) reacting a compound oftheformula: with a compound of the formula or (B) decomposing a compound of the formula or (C) treating a compound of the formula with an acid or base, and/or reducrively cleaving it.
    本发明提供了一种式中 R 为氢、甲基、乙基或丙基的 1,8-萘啶化合物及其无毒的药学上可接受的盐,一种包含上述 1,8-萘啶化合物的抗菌剂,以及一种预制上述式中 1,8-萘啶化合物的工艺,该工艺包括(A)使式中化合物:与式中化合物反应,或(B)分解式中化合物,或(C)用酸或碱处理式中化合物,和/或还原裂解式中化合物。
  • NISHIMURA, YOSHIRO;MINAMIDA, AKIRA;MATSUMOTO, JUN-ICHI, J. HETEROCYCL. CHEM., 25,(1988) N, C. 479-485
    作者:NISHIMURA, YOSHIRO、MINAMIDA, AKIRA、MATSUMOTO, JUN-ICHI
    DOI:——
    日期:——
  • MATSUMOTO, JUN-ICHI;MIYAMOTO, TERUYUKI;MINAMIDA, AKIRA;NISHIMURA, YOSHIRO+, J. HETEROCYCL. CHEM., 1984, 21, N 3, 673-679
    作者:MATSUMOTO, JUN-ICHI、MIYAMOTO, TERUYUKI、MINAMIDA, AKIRA、NISHIMURA, YOSHIRO+
    DOI:——
    日期:——
查看更多